Expert Ratings for Reviva Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Reviva Pharmaceuticals (NASDAQ:RVPH) stock, with 4 bullish and 1 somewhat bullish ratings. The company has an average 12-month price target of $15.0, up 50% from the previous average of $10.0.
June 26, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals (RVPH) has received positive ratings from 5 analysts, with an average 12-month price target of $15, a 50% increase from the previous average.
The positive ratings from 5 analysts and the increased average 12-month price target indicate a bullish sentiment towards Reviva Pharmaceuticals. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100